SHH · 600201.SS
Jinyu Bio-technology Co., Ltd.
CN¥12.12-CN¥0.49 (-3.89%)
Jinyu Bio-technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.21% below the high.
Loading market information…
SHH · 600866.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong’s quoted price sits in the lower half of its reported 52-week range, 50.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong’s forward annual dividend is CN¥0.38 per share, paid annual. The forward yield is 9.34% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong’s next earnings report is currently expected on Apr 27, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Star Lake Bioscience Co., Inc.Zhaoqing Guangdong’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Apr 21, 2025 | CN¥0.29 | CN¥4.04B+0.98% vs estimate |
|---|
| Q1 2025 | Apr 21, 2025 | CN¥0.16 | CN¥4.54B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥12.12-CN¥0.49 (-3.89%)
Jinyu Bio-technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.21% below the high.
CN¥18.75-CN¥0.04 (-0.21%)
Tibet Cheezheng Tibetan Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.84% below the high.
CN¥4.21+CN¥0.04 (+0.96%)
Zhejiang CONBA Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
CN¥26.72-CN¥0.30 (-1.11%)
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.1% below the high.
CN¥12.00CN¥0.00 (0.0%)
Zhejiang Jolly Pharmaceutical Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 35.66% below the high.
CN¥13.95-CN¥0.17 (-1.2%)
Hualan Biological Bacterin Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.96% below the high.
CN¥17.27+CN¥0.02 (+0.12%)
Vcanbio Cell & Gene Engineering Corp., Ltd’s quoted price sits in the lower half of its reported 52-week range, 47.65% below the high.
CN¥41.05-CN¥0.72 (-1.72%)
Chengdu Easton Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.99% below the high.
